Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Revlimid; Belgium: Revlimid; Bulgaria: Revlimid; Cyprus: Revlimid; Czech Republic: Revlimid; Denmark: Revlimid; Estonia: Revlimid; Finland: Revlimid; France: Revlimid; Germany: Revlimid; Greece: Revlimid; Hungary: Revlimid; Ireland: Revlimid; Italy: Revlimid; Latvia: Revlimid; Lithuania: Revlimid; Luxembourg: Revlimid; Malta: Revlimid; Netherlands: Revlimid; Poland: Revlimid; Portugal: Revlimid; Romania: Revlimid; Slovakia: Revlimid; Slovenia: Revlimid; Spain: Revlimid; Sweden: Revlimid; UK: Revlimid.

North America

Canada: Revlimid; USA: Revlimid.

Drug combinations

Lenalidomide and Dexamethasone


Lenalidomide: C~13~H~13~N~3~O~3~. Mw: 259.26. 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-. CAS-191732-72-6 (2004).

Pharmacologic Category

Antineoplastic Agents. Biologic Response Modifiers. Angiogenesis Inhibitor. Systemic Immunomodulator. (Antineoplastic Agents). (ATC-Code: L04AX04).

Mechanism of action

Selectively inhibits secretion of proinflammatory cytokines (potent inhibitor of tumor necrosis factor-α (TNF) secretion). Enhances cell-mediated immunity by stimulating proliferation of anti-CD3 stimulated T cells. Inhibits trophic signals to angiogenic factors in cells. Inhibits growth of myeloma cells by inducing cell cycle arrest and cell death.

Therapeutic use

Treatment of myelodysplastic syndrome in deletion 5q (Del 5q) cytogenetic abnormality. Treatment of multiple myeloma.

Pregnancy and lactiation implications

Lenalidomide is analog of thalidomide (a human teratogen) and could potentially cause birth defects in humans. There are no adequate studies in pregnant women. Not recommended during lactation.

Unlabeled use

Treatment of metastatic malignant melanoma. Treatment of myelofibrosis.


Hypersensitivity to lenalidomide or any component of the formulation. Pregnancy or women capable of becoming pregnant. Platelet count <50000/mm^3^. Hypersensitivity to thalidomide. Breast-feeding women.

Warnings and precautions

Hazardous agent. May cause dizziness or fatigue. Hematologic toxicity (neutropenia and thrombocytopenia) common. Increase in risk for thrombosis and embolism in multiple myeloma patients treated with combination therapy. Deep vein thrombosis and pulmonary embolism occurred. Use with caution in renal impairment. Lenalidomide is analog of thalidomide (a human teratogen) and could potentially cause birth defects in humans. Patients should not donate blood during therapy and for 4 weeks following completion of therapy. Product may contain lactose (avoid use in Lapp lactase deficiency, glucose-galactose malabsorption, or glucose intolerance).



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart